Australia Leads the World on Legal Psilocybin Therapy: What Happened
On February 3, 2023, Australia became the first country in the world to nationally authorize the use of psilocybin and MDMA as therapies. The Therapeutic Goods Administration (TGA) — Australia's equivalent of the FDA — amended the scheduling of psilocybin and MDMA, allowing authorized psychiatrists to prescribe them as treatments for specific conditions under an Authorised Prescriber scheme.
This was a landmark moment in global drug policy — the first national-level approval for therapeutic psychedelic use, predating any FDA action.
How the Australian Program Works
Regulatory structure: The TGA's decision rescheduled psilocybin from Schedule 9 (Prohibited Substances) to Schedule 8 (Controlled Drug, available by prescription) for therapeutic use. This applies specifically to:
- Psilocybin: For treatment-resistant depression
- MDMA: For post-traumatic stress disorder (PTSD)
The Authorised Prescriber pathway: Not every psychiatrist can prescribe. Psychiatrists must apply to become Authorised Prescribers, demonstrating appropriate training and protocols for administration. This is not a simple off-label prescription — it requires specific authorization.
Implementation timeline: The rescheduling took effect July 1, 2023. In practice, the first patients began receiving treatment in late 2023 and early 2024 as psychiatrists went through the authorization process and clinics established protocols.
Who Qualifies
Psilocybin for treatment-resistant depression: Patients who have:
- A confirmed diagnosis of major depressive disorder
- Failure of adequate trials of at least two different antidepressant medications
- Assessment by an authorized psychiatrist confirming treatment-resistant status
MDMA for PTSD: Patients who have:
- A confirmed PTSD diagnosis meeting DSM-5 criteria
- Failure of standard PTSD treatments (trauma-focused psychotherapy, SSRIs)
- Assessment confirming appropriateness
The Treatment Model
Treatment is conducted in clinical settings under direct medical supervision. The model follows the research protocols developed in clinical trials:
- Preparation sessions: 2–3 therapy sessions with the supervising psychiatrist and/or trained therapist
- Medicine session: A day-long supervised session (4–8 hours) in a clinical environment
- Integration sessions: 2–3 follow-up therapy sessions to process and integrate the experience
The medicine (psilocybin or MDMA) is administered in a comfortable, supportive environment with trained support staff present throughout. Patients do not take the substance home.
Why Australia Moved First
Several factors enabled Australia to act before other countries:
Evidence base: By 2023, the evidence from Hopkins, NYU, Imperial College, and multiple other institutions was substantial enough that Australia's regulatory body found it compelling.
Regulatory flexibility: The TGA's Authorised Prescriber framework allowed a narrow, controlled pathway that managed risk without requiring full FDA-style drug approval.
Political will: Australian Mental Health Minister Mark Butler and his predecessors were supportive. There was less political resistance than in other countries.
Advocacy infrastructure: Organizations like Psychedelic Research in Science & Medicine (PRISM) had been laying groundwork for years.
What It Means for Other Countries
Australia's action has had several effects globally:
Demonstrating viability: A national regulatory body has determined the evidence is sufficient for controlled therapeutic use. This provides political cover for regulators in other countries.
Generating real-world data: As Australian clinical programs mature, they will produce safety and outcomes data outside of controlled research trials — more generalizable evidence than RCTs alone.
Pressure on FDA: Australia's action increased scrutiny of FDA's timeline for psilocybin approval in the US.
Model for implementation: Australia's Authorised Prescriber model is being studied by UK, Canadian, and European regulators as a potential template.
Current Status (2026)
The Australian program continues to expand as more psychiatrists obtain authorization and more clinics establish psychedelic-assisted therapy programs. Early real-world data from Australian clinics is beginning to be published.
Several Australian research institutions — University of Melbourne, Macquarie University, and others — are conducting research in parallel with the clinical rollout. The data from these real-world treatment programs will be among the most important psychedelic research of the next decade.